Correlation Between Anebulo Pharmaceuticals and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both Anebulo Pharmaceuticals and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Anebulo Pharmaceuticals and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Anebulo Pharmaceuticals and Molecular Partners AG, you can compare the effects of market volatilities on Anebulo Pharmaceuticals and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Anebulo Pharmaceuticals with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of Anebulo Pharmaceuticals and Molecular Partners.
Diversification Opportunities for Anebulo Pharmaceuticals and Molecular Partners
-0.04 | Correlation Coefficient |
Good diversification
The 3 months correlation between Anebulo and Molecular is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Anebulo Pharmaceuticals and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and Anebulo Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Anebulo Pharmaceuticals are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of Anebulo Pharmaceuticals i.e., Anebulo Pharmaceuticals and Molecular Partners go up and down completely randomly.
Pair Corralation between Anebulo Pharmaceuticals and Molecular Partners
Given the investment horizon of 90 days Anebulo Pharmaceuticals is expected to under-perform the Molecular Partners. In addition to that, Anebulo Pharmaceuticals is 1.59 times more volatile than Molecular Partners AG. It trades about -0.01 of its total potential returns per unit of risk. Molecular Partners AG is currently generating about -0.01 per unit of volatility. If you would invest 499.00 in Molecular Partners AG on December 30, 2024 and sell it today you would lose (43.00) from holding Molecular Partners AG or give up 8.62% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 100.0% |
Values | Daily Returns |
Anebulo Pharmaceuticals vs. Molecular Partners AG
Performance |
Timeline |
Anebulo Pharmaceuticals |
Molecular Partners |
Anebulo Pharmaceuticals and Molecular Partners Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Anebulo Pharmaceuticals and Molecular Partners
The main advantage of trading using opposite Anebulo Pharmaceuticals and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Anebulo Pharmaceuticals position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.Anebulo Pharmaceuticals vs. Adagene | Anebulo Pharmaceuticals vs. Acrivon Therapeutics, Common | Anebulo Pharmaceuticals vs. AnaptysBio | Anebulo Pharmaceuticals vs. Mineralys Therapeutics, Common |
Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |